secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2025-07-15T23:59:59+00:00
Accession:  0001104659-25-067951
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud

BioXcel Therapeutics receives USPTO allowance for key IGALMI patent expiring 2043
--------------------------------------------------------------------------------

- USPTO allowed U.S. Patent Application No. 18/600,419 for single-dose oromucosal dexmedetomidine up to 120 mcg.
- Claims cover acute agitation treatment in schizophrenia or bipolar disorder with QT prolongation <6 microseconds.
- Allowed claims mirror the recommended IGALMI dosing regime for that patient subpopulation.
- This will be the 14th Orange Book-listed patent for IGALMI, expiring January 12, 2043 subject to adjustment.
- CFO Richard Steinhart signed the 8-K filed July 15, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925067951/0001104659-25-067951-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465925067951/tm2520959d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-067951

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer